Jin Fangqian, Global Vice President of Gilead Sciences: Continue to increase investment in China and bring Chinese innovative drugs to the world
阿豆学长长ov
发表于 2024-11-7 13:30:52
138
0
0
We are already participating in the CIIE for the third time. In the past few years, with the platform of the CIIE, we have been able to share our research and development achievements and business progress, while also accelerating the launch of our innovative products in China, benefiting more groups as soon as possible. Finally, we have also carried out multi-party cooperation through the CIIE platform, signed contracts with various partners, and accelerated our development process in China. "During the 7th CIIE, Jin Fangqian, Global Vice President and General Manager of Gilead Science in China, said in an interview with media such as Times Finance.
At this year's CIIE, Gilead Science announced for the first time the significant progress of its core product Lenacapavir in the field of HIV prevention.
Lenacapavir is the world's first approved HIV capsid inhibitor drug and a long-acting HIV treatment regimen that only requires two doses per year. The drug has been approved in the European Union and the United States for use in combination with other antiretroviral drugs to treat multidrug-resistant HIV-1 adults who have previously received multiple treatment regimens.
In June this year, Gilead announced that the interim analysis results of Lenacapavir's key phase 3 PURPOSE 1 showed that the drug showed 100% effectiveness in HIV (AIDS) prevention among transgender women; Less than three months later, Gilead once again stated to the public that the mid-term analysis results of PURPOSSE 2 showed that 99.9% of subjects using Lenacapavir did not develop HIV infection. Compared to the background HIV incidence rate (bHIV), Lenacapavir reduced the HIV infection rate by 96%.
Since its debut at the CIIE last year, in less than a year, Lenacapavir has made continuous progress in clinical trials, which may revolutionize HIV prevention plans. According to Gilead, Gilead has submitted a marketing application for Lenacapavir for HIV treatment to the Chinese drug review department.
Gilead's innovative drug Seladelar also made its debut in China at this year's CIIE. The drug received accelerated approval from the US Food and Drug Administration (FDA) in August 2024, providing a new option for second-line treatment of patients with primary biliary cholangitis. As a chronic autoimmune intrahepatic cholestasis disease, primary biliary cholangitis (PBC) is an easily overlooked "hidden killer" of the liver, and has been included in the "Second Batch of Rare Diseases" catalog released by the National Health Commission in 2023.
In addition, over 10 drugs from Gilead in the fields of HIV prevention and treatment, viral hepatitis, oncology, and antifungal therapy are also exhibited at the CIIE.
At present, China has become an important part of the global biopharmaceutical industry, and the Chinese market has become one of the important pillars of global business for many multinational pharmaceutical companies.
Gilead told Time Finance before this year's CIIE that this year marks the 40th anniversary of the Drug Administration Law. Since its promulgation in 1984, the Drug Administration Law has undergone several revisions and developments, among which the accelerated review and approval of new drugs has provided great convenience for innovative drugs to enter the Chinese market, enabling multinational pharmaceutical companies like Gilead to quickly introduce innovative drugs into China and meet the treatment needs of patients. In 2018 alone, Gilead had five innovative drugs approved in the field of chronic hepatitis B B, hepatitis C and HIV treatment.
Thanks to the improvement of medical insurance policies, as of now, 8 out of the 11 drugs listed by Gilead in China have been included in the national medical insurance catalog.
Jin Fangqian told Time Finance, "China has always been a very important market for us, and we will continue to increase our investment in China, including the launch of new products, expansion of market coverage, patient benefits, research and development, etc. In the future, we will also carry out more global Phase III clinical trials, and even earlier Phase II and I clinical trials in China. At the same time, on the one hand, we hope to bring more innovative products to China, and on the other hand, we also hope to cooperate with local Chinese enterprises to bring Chinese products to the world
Starting from 2022, Gilead will establish a local R&D team and capabilities in China, continuously increasing investment in local R&D and promoting the simultaneous launch of innovative drugs globally and domestically. As of now, the R&D team of Gilead China has exceeded 150 people, promoting the rapid development of about 20 clinical research projects in China. While Gilead continues to invest in drug research and development, it is also constantly exploring innovative models to help improve drug accessibility.
Facing the rapid changes in the global pharmaceutical market and competitive environment, how to maintain competitiveness is a proposition that major players need to consider. Firstly, in order to maintain competitiveness in the market, product innovation is needed to truly address some unmet treatment needs. Secondly, we must accelerate the commercialization process. Our logic is to leverage the power of various partners to accelerate our commercialization process, "Jin Fangqian said to Time Finance during the CIIE.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- Tesla China's latest statement: not true! Trump suddenly spreads big news! Has Musk become a big winner again?
- Johnson&Johnson China reported layoffs! Layoff employees: Surgical department has the highest number of layoffs
- Former Baidu Vice President Yin Shiming joins Google Cloud
- The Nasdaq China Golden Dragon Index closed up 1.71%, with most popular Chinese concept stocks rising
- The Nasdaq China Golden Dragon Index closed up 1.71%, with most popular Chinese concept stocks rising
- Yum China repurchases 50000 shares and pays approximately $2.4 million
- FSD authorizes SAIC to layout Robotaxi? Tesla China: Never Connected
- Starbucks responds to rumors of 'considering selling shares in China business': committed to developing in China and striving to find the best growth path
- Starbucks responds to rumors of considering selling equity in its China business: committed to long-term development in the Chinese market and striving to find the best growth path
- The Nasdaq China Golden Dragon Index closed down 1%, with most popular Chinese concept stocks falling
-
11月21日、2024世界インターネット大会烏鎮サミットで、創業者、CEOの周源氏が大会デジタル教育フォーラムとインターネット企業家フォーラムでそれぞれ講演、発言したことを知っている。周源氏によると、デジタル教 ...
- 不正经的工程师
- 昨天 16:36
- 支持
- 反对
- 回复
- 收藏
-
アリババは、26億5000万ドルのドル建て優先無担保手形と170億元の人民元建て優先無担保手形の定価を発表した。ドル債の発行は2024年11月26日に終了する予定です。人民元債券の発行は2024年11月28日に終了する予定だ ...
- SOGO
- 3 天前
- 支持
- 反对
- 回复
- 收藏
-
スターバックスが中国事業の株式売却の可能性を検討していることが明らかになった。 11月21日、外国メディアによると、スターバックスは中国事業の株式売却を検討している。関係者によると、スターバックスは中国事 ...
- 献世八宝掌
- 前天 16:29
- 支持
- 反对
- 回复
- 收藏
-
【意法半導体CEO:中国市場は非常に重要で華虹と協力を展開】北京時間11月21日、意法半導体(STM.N)は投資家活動の現場で、同社が中国ウェハー代工場の華虹公司(688347.SH)と協力していると発表した。伊仏半導体 ...
- 黄俊琼
- 前天 14:29
- 支持
- 反对
- 回复
- 收藏